This difference of clinical outcome might be explained by the concentration of BCR-ABL TKIs necessary to obtain a same degree of PDGFR inhibition.43Indeed, Rivera et al reported that when adjusted to the maximum serum concentration, imatinib inhibits more profoundly PDGFR than dasatinib, nilotinib, and ponatinib.43Therefore, at effective concentration, it is probable that the degree of PDGFR inhibition is too low with dasatinib, nilotinib, and ponatinib to obtain the beneficial effect of PDGFR inhibition on atherosclerosis. The gene discussed is ABL1; the disease is atherosclerosis.